ArticleFrontiers in oncology2025

Comprehensive risk profiling and long-term cardiovascular toxicity in HER2-positive breast cancer patients treated with trastuzumab.

Minjing Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.